Anti-TIF1γ (p155/140) is reported in 23–29% of patients with JDM and is associated with more severe skin disease, development of skin ulceration and a long disease course (58), while anti-NXP2 (p140) is mainly connected with the development of calcinosis in pediatric cases (59). The gene discussed is TRIM33; the disease is juvenile dermatomyositis.